Molecular Pharmacology (USA), Ltd.
OTC: MLPH0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeffrey David Edwards
- Employees
- 1
- Headquarters
- Perth, Australia
- IPO year
- 2009
- Market cap
- $403.8K
- Website
- https://molpharm.aspetjournals.org/
Loading MLPH…
Loading profile data…Frequently asked questions about MLPH
What does Molecular Pharmacology (USA), Ltd. (MLPH) do?
As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory mol...
Where does MLPH trade?
Molecular Pharmacology (USA), Ltd. (MLPH) trades on the Other OTC.
What sector is MLPH in?
Molecular Pharmacology (USA), Ltd. (MLPH) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Molecular Pharmacology (USA), Ltd.?
Jeffrey David Edwards is the chief executive officer of Molecular Pharmacology (USA), Ltd. (MLPH).
Where is Molecular Pharmacology (USA), Ltd. headquartered?
Molecular Pharmacology (USA), Ltd. is headquartered in Australia.
Does MLPH pay a dividend?
Molecular Pharmacology (USA), Ltd. (MLPH) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MLPH go public?
Molecular Pharmacology (USA), Ltd. (MLPH) completed its initial public offering in 2009.